C-terminal peptide of procollagen I, N-terminal peptide of procollagen III, collagen IV and serum prolyl hydroxylase were measured in 100 patients with cirrhosis and 71 patients with noncirrhotic chronic liver disease. Patients with cirrhosis had significantly higher mean values of prolyl hydroxylase, collagen IV, N-terminal peptide of procollagen III and C-terminal peptide of procollagen I as compared to noncirrhotic patients. This difference was maintained for collagen products even after stratification for alcohol intake, although all markers of fibrosis were higher in alcoholics. Stepwise logistic regression analysis showed that collagen IV, and N-terminal peptide of procollagen III were independently associated with cirrhosis. Receiver-operating characteristic (ROC) curves showed that collagen IV and N-terminal peptide of procollagen III perform more efficiently than C-terminal peptide of procollagen I and prolyl hydroxylase in identifying cirrhosis.
FroehlichFLamyOFriedMGonversJJ. Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci1993; 38: 1480–4.
2.
GilmoreITBurroughsAMurray-LyonIMWilliamsRJenkinsDHopkinsA. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: An audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut1995; 36: 437–41.
3.
PlebaniMBurlinaA. Biochemical markers of hepatic fibrosis. Clin Biochem1991; 24: 219–39.
4.
GrimbertSTrinchetJ-CHartmannDJMunzCGarnierMMalFComparaison de 6 marqueurs sériques potentiels de la fibrose hépatique au cours de la maladie alcoolique du foie. Gastroentérol Clin Biol1993; 17: 570–7.
5.
ShahinMSchuppanDWaldherrRSerum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease. Hepatology1992; 15: 637–44.
6.
LinDyChuCMSheenISLiawYF. Serum carboxy terminal propeptide of type I procollagen to amino terminal propeptide of type III procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases. Dig Dis Sci1995; 40: 21–7.
7.
MüllerAKrombholzBPottGMachnikGVollandtRReinhardtMCollagen peptidase and type III procollagen peptide serum levels in chronic liver disease. Clin Chim Acta 1001; 197: 59–66.
8.
TeareJPShermanDGreenfieldSMSimpsonJBrayGCatterallAPComparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet1993; 342: 895–8.
9.
UenoTInuzukaSTorimuraTOohiraHKoHObataKSignificance of serum type-IV collagens levels in various liver diseases. Measurement with a one-step sandwich enzyme immunoassay using monoclonal antibodies with specificity for pepsin-solubilized type-IV collagen. Scand J Gastroenterol1992; 27: 513–20.
10.
FabrisCPirisiMFalletiESoardoGGonanoFBartoliE. Prediction of serum markers of fibrosis by levels of circulating intercellular adhesion molecule-1 in acute and chronic liver disease. Clin Biochem1994; 27: 407–12.
11.
MurawakiYKusakabeYHirayamaC. Serum lysyl oxidase activity in chronic liver disease in comparison with serum levels of prolyl hydroxylase and laminin. Hepatology1991; 14: 1167–73.
12.
MiyaharaMNjiehaRKProckopDJ. Formation of collagen fibrils in vitro by cleavage of procollagen with procollagen proteinases. J Biol Chem1982; 257: 8442–8.
13.
RojkindMGiambroneM-ABiempicaL. Collagen types in normal and cirrhotic liver. Gastroenterology1979; 76: 710–9.
14.
ProckopDJKivirickoKI. Collagens: Molecular biology, diseases, and potentials for therapy. Annu Rev Biochem1995; 64: 403–34.
15.
BrazelDPollnerRKuhnK. Human basement membrane collagen (type IV): The amino acid sequence of the alpha 2(IV) chain and its comparison with the alpha 1(IV) chain reveals deletions in the alpha 1(IV) chain. Eur J Biochem1988; 172: 35–42.
16.
Kuutti-SavolainenERRisteliJMiettinenTAKivirikkoKI. Collagen biosynthesis enzymes in serum and hepatic tissue in liver disease. 1. Prolyl hydroxylase. Eur J Clin Invest1979; 9: 89–95.
17.
ChichesterCOFullerGG. Evidence for the presence of an endogenous inhibitor of prolyl hydroxylase. Res Commun Chem Pathol Pharmacol1980; 29: 329–38.
18.
HahnEG. Blood analysis for liver fibrosis. J Hepatol1985; 1: 67–73.
19.
RaedeschRStiehlASiegAWalkerSKommerellB. Biliary excretion of procollagen type III peptide in healthy humans and in patients with alcoholic cirrhosis of the liver. Gastroenterology1983; 85: 1265–70.
20.
SmedsrodBPertoftHGustafsonSLaurentTC. Scavenger functions of the liver endothelial cell. Biochem J1990; 266: 313–27.
21.
WuJDanielssonÅDetection of hepatic fibrogenesis: A review of available techniques. Scand J Gastroenterol1995; 30: 817–25.
22.
NiemeläORisteliJBlakeJERisteliLComptonKVOrregoH. Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology1990; 98: 1612–9.
23.
MannSWFullerGCRodilJVVidinsEI. Hepatic prolyl hydroxylase and collagen synthesis in patients with alcoholic liver disease. Gut1979; 20: 825–32.
24.
NagaiYYoshibaM. Studies on serum immunoreactive prolyl 4-hydroxylase in liver diseases—its elevation both in hepatocellular damage and cholestatic diseases. Clin Chim Acta1988; 175: 27–36.
